• Mario Detomas, Miriam Reuter, and Timo Deutschbein.
• Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik I, Lehrstuhl für Endokrinologie und Diabetologie, Würzburg; Medicover Oldenburg MVZ, Oldenburg.
• Dtsch. Med. Wochenschr. 2021 Aug 1; 146 (15): 950-954.

AbstractAcromegaly is a rare but severe disorder which is usually due to an excessive secretion of growth hormone (GH) by a pituitary adenoma. Screening mainly relies on the measurement of insulin-like growth factor 1, and confirmatory diagnostics includes a GH suppression test. As delayed diagnosis results in increased morbidity and mortality, we here discuss recently published suggestions regarding the biochemical work-up of suspected cases and the follow-up of co-morbidities. Moreover, new analytical tools (such as automatic identification of typical facial changes using artificial intelligence) are presented, hopefully allowing for an earlier diagnosis in the future. So far, surgery is still regarded as therapy of first choice. In cases without postoperative remission, a new imaging approach (combining sellar magnetic resonance imaging and position emission tomography) may improve the results of repeated surgery. The pharmaceutical arsenal now includes the first orally available somatostatin analogue, and recent data on possible drug combinations and the outcome of radiotherapy are presented. Finally, special attention is paid to older and pregnant patients, as well as certain considerations during the COVID-19 pandemic (where appropriate diagnosis and management of acromegaly is particularly challenging).Thieme. All rights reserved.

35 keywords...

hide…